Alkermes plc

Alkermes plc

ALKSNYSE / NASDAQHealthcareMid cap

$44.94-$1.24 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$7.2B
P/E
29.9x
EV / EBITDA
20.9x
Revenue
$1.5B
Net margin
16.4%
ROCE
13.1%

+59.4% over the last year

Alkermes plc price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+1.9%
3M
-6.4%
6M
+21.5%
1Y
+59.4%
5Y
+93.4%

52-week range

Day change -$1.24 (-2.7%) from $46 to $45 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ALKS, bought on each weekday since 2021.

News & filings

What Alkermes filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 17.2% against a peer median of 9.4%.

Concerns (1)

  • The P/E of 29.9 is 166% above the peer median of 11.2.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Read moreShow less

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Shares outstanding
164.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.2B
P/E
29.9x
P/B
4.0x
EV / EBITDA
20.9x
EV / Sales
4.7x
P/S
4.9x
52-week high
$55.22
52-week low
$27.20

Profitability

Operating margin
17.2%
Net margin
16.4%
EBITDA margin
22.4%
ROE
13.3%
ROCE
13.1%
ROA
9.7%
Asset turnover
0.59

Growth

Revenue
$1.5B
Revenue growth, 1Y
-5.2%
Revenue CAGR, 3Y
9.9%
Net profit growth, 1Y
-34.2%
Free cash flow
$480.3M

Solvency

Current ratio
3.55
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
2.15
Cash / Market cap
5.4%

Where the revenue went

Of every $100 of FY2025 revenue, $16 was left as net income.

Alkermes plc income statement flow, FY2025
Alkermes plc income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$196.5M
RevenueGross profit$1.3B
Gross profitResearch and development$324.0M
Gross profitSelling, general and administrative$701.5M
Gross profitOther operating expenses$0.00
Gross profitOperating income$254.0M
Operating incomePretax income$254.0M
Interest and other incomePretax income$37.5M
Pretax incomeTax and other$49.8M
Pretax incomeNet income$241.7M

Revenue and net profit

Revenue fell 5.2% in FY2025; net profit is the dashed line.

Alkermes plc revenue and net profit by fiscal year
Alkermes plc revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.1B-$158.3M
FY2023$1.7B$355.8M
FY2024$1.6B$367.1M
FY2025$1.5B$241.7M

Cash flows

FY2025: $520.8M from operations, $480.3M free after investment (dashed).

Alkermes plc operating and free cash flow by fiscal year
Alkermes plc operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$21.0M-$17.2M
FY2023$401.4M$353.3M
FY2024$439.1M$405.6M
FY2025$520.8M$480.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.5B-5.2%1Y
EBITDA
$330.9M-33.1%1Y
Net profit
$241.7M-34.2%1Y
Cash from operations
$520.8M+18.6%1Y
Free cash flow
$480.3M+18.4%1Y
Revenue CAGR, 3Y
9.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.5B$330.9M$241.7M$480.3M13.3%-5.2%-34.2%

Monthly returns

Month-by-month returns of ALKS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.5B
Liabilities$667.7M
Equity$1.8B
Paid-in capital$3.0B
Retained earnings-$734.8M
Treasury stock$450.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ALKS highlighted.

P/E against peers

ALKS trades at 29.9x earnings against a peer median of 11.2x (a 166% premium).

Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Alkermes plcALKSthis companyP/E ↑ premium$7.2B29.9x4.0x13.3%20.9x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
PTC Therapeutics, Inc.PTCT$5.9B8.6x—-332.5%7.5x
Teleflex IncorporatedTFX$5.8B-6.5x1.9x-29.0%27.1x
Peer median—11.2x9.6x-8.7%19.8x

Year-to-date ROI

ALKS since 1 January, against earlier years.

Historical volatility

ALKS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Alkermes plc operating margin by fiscal year
Alkermes plc operating margin by fiscal year
DateOperating margin
FY2022-0.5%
FY202324.9%
FY202427.0%
FY202517.2%
LineFY2025
Cost of revenueCost Of Revenue$196.5M
Gross profitGross Profit$1.3B
Operating expensesOperating Expense$1.0B
Research and developmentResearch And Development$324.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$0.00
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$0.00
Amortization$0.00
Amortisation of intangiblesAmortization Of Intangibles Income Statement$0.00
Total expensesTotal Expenses$1.2B
Pretax incomePretax Income$291.4M

Learn while you research

Academy chapters picked for Alkermes plc and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →